Operating as a clinical-stage biopharmaceutical entity, Anavex Life Sciences Corp. specializes in developing therapeutic drug candidates for various central nervous system (CNS) conditions.
52W Range
9thpctl
Volume
0.81×avg
Market Cap
277.09MUSD
P/E Ratio
-11.4TTM
Div Yield
-ann
Loading chart data...
Current StateState loading
Anavex Life Sciences Corp.
AVXLNASDAQ Global Select·USD·Closed
Anavex Life Sciences Corp.
AVXLNASDAQ·USD·Closed
$2.99
−4.47%
$2.99
−$0.14 (4.47%)
52W Range
9thpctl
Volume
0.81×avg
Mkt Cap
277.09MUSD
P/E
-11.4TTM
Div Yield
–ann
AVXL: Anavex Life Sciences Corp. Stock Analysis | finqOS
